Last updated on September 2018

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Brief description of study

The primary objective of the study is to determine the ability of reslizumab administered sc to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils, without loss of asthma control.

Clinical Study Identifier: NCT02501629

Contact Investigators or Research Sites near you

Start Over

Teva Medical Information

Teva Investigational Site 87024
Jeonju, Korea, Republic of